| Literature DB >> 24917892 |
Waldemar Jedynak1, Andrzej Cieszanowski2.
Abstract
Summary Though the etiology of multiple sclerosis remains unknown, the widely accepted explanation is that it has an autoimmune inflammatory background. In 2006 Paolo Zamboni renewed the somewhat forgotten vascular theory of the pathogenesis of multiple sclerosis, proposing the new entity of 'chronic cerebrospinal venous insufficiency'. As a result of this hypothesis, Zamboni suggested an endovascular treatment for multiple sclerosis involving venoplasty of the internal jugular vein and the azygos vein. Unfortunately, several teams have tried to replicate Zamboni's results without success. In this review, we present a chronological description of the results of the studies conducted by Zamboni and the later attempts to replicate his work. The main conclusion is that, taking into account results that are currently available, we should remain cautious and routine use of this treatment in patients should not be advisable.Entities:
Keywords: CCSVI; Multiple Sclerosis; Venoplasty
Year: 2014 PMID: 24917892 PMCID: PMC4049975 DOI: 10.12659/PJR.890379
Source DB: PubMed Journal: Pol J Radiol ISSN: 1733-134X
Ultrasound criteria of the chronic cerebrospinal venous insufficiency (CCSVI).
| Chronic cerebrospinal venous insufficiency (CCSVI) criteria according to Zamboni [ |
|---|
| 1. Reflux constantly present in an outflow pathway (IJV and/or VV) with the head in any position. |
| 2. Reflux propagated upward to the DCVs. |
| 3. High resolution B-mode ultrasonography evidence of proximal IJV stenoses. |
| 4. Flow not CD detectable in the IJVs and/or VVs despite numerous deep inspirations. |
| 5. Negative ΔCSA in the IJV. |
IJV(s) – internal jugular vein(s); VV(s) – vertebral vein(s); DCVs – deep cerebral veins; CD – color Doppler; ΔCSA – change in the cross-sectional area.
Figure 1Internal jugular vein reflux.
Figure 3Segmental stenoses within the internal jugular veins.
Prevalence of CCSVI in multiple sclerosis patients vs. controls – selected studies.
| Authors | MS patients | Non-MS patients | Positive CCSVI criteria in MS patients [%] | Positive CCSVI criteria in non-MS patients[%] |
|---|---|---|---|---|
| Zamboni P. et al. [ | 65 | 235 | 100% | 0% |
| Al-Omari M.H. et al. [ | 25 | 25 | 84% | 0% |
| Doepp F. et al. [ | 56 | 20 | 0% | 0% |
| Baracchini C. et al. [ | 50 | 50 | 16% | 2% |
| Mayer C.A. et al. [ | 20 | 20 | 0% | 5% |
| Zivadinov R. et al.[ | 289 | 163 | 56.1% | 22.7% |
| Floris R. et al. [ | 40 | 34 | 55% | 35% |
| Patti F. et al. [ | 148 | 172 | 18.9% | 6.4% |
| Lanzillo R. et al. [ | 146 | 38 | 76% | 16% |
| Leone M.A. et al. [ | 68 | 68 | 30.9% | 33.8% |
| Van den Berg P.J. et al. [ | 90 | 41 | 9% | 0% |
| Chambers B. et al. [ | 70 | 70 | 0% | 1.4% |
| Barreto A.D. et al. [ | 200 | 76 | 3.88% | 7.14% |
| Imperiale D. et al. [ | 80 | 41 | 17.5% | 7.3% |
| Rodger I.W. et al. [ | 99 | 100 | 1% | 0% |
| Brod S.A. et al. [ | 206 | 70 | 3.88% | 7.14% |
| Comi G. et al. [ | 1165 | 376 | 3.26% | 2.13% |
| Traboulsee A.L. et al. [ | 79 | 43 | 44% | 45% |
| Tromba L. et al. [ | 112 | 67 | 59.8% | 0% |